Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer

NCT06292689 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.

NCT NCT06292689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06292689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer
Lead sponsor
Zhejiang Cancer Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
March 22, 2024
Completion date
March 22, 2027
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

vulvar and vaginal cancer